|
Alcoholic Intoxication, Chronic
|
0.300 |
Biomarker
|
disease |
PSYGENET |
DARPP-32 (dopamine and adenosine 3',5'-monophosphate-regulated phosphoprotein, 32 kDa) is an important component of dopaminergic function in brain areas thought to be important for drug and alcohol addiction.
|
11150351 |
2001 |
|
Malignant neoplasm of stomach
|
0.080 |
Biomarker
|
disease |
BEFREE |
Gastric cancers overexpress DARPP-32 and a novel isoform, t-DARPP.
|
12124342 |
2002 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Immunohistochemical analysis of tissue microarrays that contained 187 carcinoma samples confirmed the strong expression of DARPP-32 proteins in these tumor types.
|
14508844 |
2003 |
|
Carcinogenesis
|
0.080 |
AlteredExpression
|
phenotype |
BEFREE |
Moreover, the observation that DARPP-32 and t-DARPP frequently are overexpressed in common subtypes of human adenocarcinomas suggest that these proteins may be important in tumorigenesis.
|
14508844 |
2003 |
|
Adenocarcinoma
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Moreover, the observation that DARPP-32 and t-DARPP frequently are overexpressed in common subtypes of human adenocarcinomas suggest that these proteins may be important in tumorigenesis.
|
14508844 |
2003 |
|
Adenocarcinoma
|
0.020 |
AlteredExpression
|
group |
LHGDN |
Moreover, the observation that DARPP-32 and t-DARPP frequently are overexpressed in common subtypes of human adenocarcinomas suggest that these proteins may be important in tumorigenesis.
|
14508844 |
2003 |
|
Carcinoma
|
0.020 |
Biomarker
|
group |
BEFREE |
Using tissue microarrays and an antibody to DARPP-32, the authors evaluated the immunohistochemical findings in 43 different normal epithelium human tissue samples and in 187 samples of common carcinomas of breast, prostate, colon, and stomach.
|
14508844 |
2003 |
|
Huntington Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Non-enriched HD mice also exhibit deficits in dopamine and cAMP-regulated phosphoprotein (32 kDa) in striatum and anterior cortex.
|
14999077 |
2004 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These observations suggest that DARPP-32 (rather than t-DARPP) expression arises after a phase of dysplasia in OSCC, and that tumours expressing DARPP-32 progress less rapidly than DARPP-32-negative tumours.
|
15188007 |
2004 |
|
Malignant neoplasm of breast
|
0.080 |
Biomarker
|
disease |
BEFREE |
PPP1R1B-STARD3-TCAP-PNMT-PERLD1-ERBB2-MGC14832-GRB7 locus at human chromosome 17q12 is frequently amplified in human gastric cancer and breast cancer.
|
15010812 |
2004 |
|
Malignant neoplasm of stomach
|
0.080 |
Biomarker
|
disease |
BEFREE |
PPP1R1B-STARD3-TCAP-PNMT-PERLD1-ERBB2-MGC14832-GRB7 locus at human chromosome 17q12 is frequently amplified in human gastric cancer and breast cancer.
|
15010812 |
2004 |
|
Carcinogenesis
|
0.080 |
AlteredExpression
|
phenotype |
BEFREE |
A recent study demonstrated that DARPP-32, and a truncated isoform t-DARPP, are overexpressed in gastric carcinoma during the process of carcinogenesis.
|
15188007 |
2004 |
|
Breast Carcinoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
PPP1R1B-STARD3-TCAP-PNMT-PERLD1-ERBB2-MGC14832-GRB7 locus at human chromosome 17q12 is frequently amplified in human gastric cancer and breast cancer.
|
15010812 |
2004 |
|
Stomach Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
PPP1R1B-STARD3-TCAP-PNMT-PERLD1-ERBB2-MGC14832-GRB7 locus at human chromosome 17q12 is frequently amplified in human gastric cancer and breast cancer.
|
15010812 |
2004 |
|
Drug abuse
|
0.040 |
Biomarker
|
group |
BEFREE |
This review focuses on the critical role that DARPP-32 plays in mediating the actions of a broad range of drugs of abuse.
|
15464122 |
2004 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
This is the first report to correlate DARPP-32 immunoreactivity (dopamine and cAMP-regulated phosphoprotein, M(r) 32 000) to clinicopathological status in human cancer.
|
15188007 |
2004 |
|
Stomach Neoplasms
|
0.030 |
AlteredExpression
|
group |
LHGDN |
Coamplified and overexpressed genes at ERBB2 locus in gastric cancer.
|
14991576 |
2004 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
This is the first report to correlate DARPP-32 immunoreactivity (dopamine and cAMP-regulated phosphoprotein, M(r) 32 000) to clinicopathological status in human cancer.
|
15188007 |
2004 |
|
Squamous cell carcinoma of esophagus
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Initially, we investigated DARPP-32 and t-DARPP expression in OSCC cell lines by Reverse transcription-polymerase chain reaction and Western blot.
|
15188007 |
2004 |
|
Squamous cell carcinoma
|
0.010 |
AlteredExpression
|
disease |
LHGDN |
DARPP-32 expression arises after a phase of dysplasia in oesophageal squamous cell carcinoma.
|
15188007 |
2004 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Concomitant overexpression of mRNA for Darpp-32 and its truncated isoform t-Darpp was observed in 68% of tumors (P < 0.001).
|
16061638 |
2005 |
|
Carcinoma
|
0.020 |
Biomarker
|
group |
BEFREE |
Darpp-32: a novel antiapoptotic gene in upper gastrointestinal carcinomas.
|
16061638 |
2005 |
|
Schizophrenia
|
0.600 |
Biomarker
|
disease |
BEFREE |
Hence, our results suggest that the reduced DARPP-32 protein in patients with schizophrenia is unlikely caused by mutations in the DARPP-32 gene itself and the DARPP-32 gene is also unlikely a major susceptibility gene for schizophrenia.
|
16750903 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In the DRD2/DARPP-32 combination, the (+/-) group was significantly correlated with pathologic stage (P = 0.0006), lymph node metastasis (P = 0.0001), pT (P = 0.0287), and tumor size (P = 0.0202).
|
16850143 |
2006 |
|
Mammary Neoplasms
|
0.050 |
Biomarker
|
group |
LHGDN |
Mutational substitution of the phosphorylation sites Thr-34 or Thr-75 on DARPP-32 revealed that phosphorylation of Thr-34 is necessary for the ability of DARPP-32 to impair breast tumor cell migration.
|
17027969 |
2006 |